Diabetologische Schwerpunktpraxis, Frankfurt am Main
Germany
Vortrag
Efficacy and Safety of Switching from Sitagliptin (SITA) to Liraglutide (LIRA) in Subjects with Type 2 Diabetes (T2D) Not Achieving Adequate Glycaemic Control on SITA and Metformin (MET): A Post Hoc Subgroup Analysis Defined by Baseline BMI < or ≥30 kg/m2
Speaker